[by Lee, Young Sung] Celltrion announced on April 28 that it has received approval from the Ministry of Food and Drug Safety for the Phase 3 clinical trial plan for 'CT-P51,' a biosimilar candidate to Keytruda. This study will be conducted as a global phase 3 clinical trial, with Korea included among the approved sites.
Through this phase 3 clinical trial, 메이저 바카라사이트 유니88벳 will evaluate the efficacy and safety of 'CT-P51' compared to 'Keytruda,' in combination with platinum-pemetrexed chemotherapy, in 606 patients with metastatic non-squamous non-small cell lung cancer who have not received prior treatment. The study is expected to be conducted over a period of approximately two years.
"We anticipate expanding our market presence and increasing sales by obtaining approval for all indications, including not only metastatic non-squamous non-small cell lung cancer but also other types of non-small cell lung cancer for which the original drug has been approved," a 메이저 바카라사이트 유니88벳 official said.